Welcome to our dedicated page for Senseonics Holdings news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings stock.
Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.
The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.
Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.
Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.
FAQ
What is the current stock price of Senseonics Holdings (SENS)?
The current stock price of Senseonics Holdings (SENS) is $1.01 as of January 23, 2025.
What is the market cap of Senseonics Holdings (SENS)?
The market cap of Senseonics Holdings (SENS) is approximately 580.9M.
What does Senseonics Holdings, Inc. specialize in?
Senseonics specializes in developing and commercializing advanced glucose monitoring systems for diabetes management, featuring the first fully implantable CGM system.
What is the Eversense Continuous Glucose Monitoring (CGM) System?
The Eversense CGM System is a breakthrough glucose monitoring solution that includes a small sensor implanted under the skin, an external smart transmitter, and a mobile app for real-time glucose data.
How long can the Eversense CGM System monitor glucose levels?
The Eversense CGM System can continuously monitor glucose levels for up to 180 days, offering a long-term solution compared to traditional short-term CGMs.
What is the Eversense Payment Assistance and Simple Savings (PASS) Program?
The PASS Program is designed to make the Eversense E3 CGM System more affordable by offering eligible individuals in the U.S. the system at a reduced cost of $99 for each six-month period.
How does Senseonics' CGM technology benefit people with diabetes?
The CGM technology provides highly accurate, stable, and long-term glucose monitoring, enabling people with diabetes to manage their condition confidently and with ease.
Where is Senseonics Holdings, Inc. headquartered?
Senseonics Holdings, Inc. is headquartered in Germantown, Maryland, USA.
Who are Senseonics' key partners?
Senseonics has key partnerships with companies like Ascensia Diabetes Care, which helps in the global distribution and accessibility of their products.
How can I learn more about the Eversense CGM System?
You can visit Ascensia Diabetes Care's website or contact their support line to get detailed information about the Eversense CGM System and eligibility for the PASS Program.
Is the Eversense CGM System available outside the United States?
Yes, the Eversense CGM System is available globally, and Senseonics generates a significant portion of its revenue from markets outside the United States.
What is the mission of Senseonics Holdings, Inc.?
The mission of Senseonics is to transform the lives of people with diabetes through innovative, long-term implantable glucose management technology.